# Fraser

> Fraser is a VC fund in London backing Health Care and Biotechnology. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 16
- Last investment: Oct 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/fraser-finance/
- Website: https://www.fraserfinance.com

Fraser is a dedicated M&A advisory and investment firm, partnering with leaders in Europe’s B2B technology sectors to unlock next levels of growth & success. Based in Berlin, London and Chicago, we advise entrepreneurs, senior management and boards on their most important strategic decisions and transactions. Alongside our clients andpartners, we also invest into selected opportunities.Since 2005, we have completed over $1BN of transactions, incl. ADTECH AG (acquired by AOL), 3GNet GmbH (acquired by iCrossing and subsequently sold to Hearst), UDG (backed with $100M+ by EQT and recently merged with PIA Performance Interactive Alliance), nugg.ad AG (acquired by Deutsche Post DHL and then sold to Zalando), Optivo GmbH (acquired by Deutsche Post DHL), explido GmbH (acquired by Dentsu Aegis Network and combined to form explido iProspect), Adglow (acquisition of Glow), Episerver AB (acquisition of Optivo GmbH, backed by Accel-KKR), Tessian (backed by Sequoia), diffferent GmbH (acquired by Syzygy, part of WPP), and m-pathy GmbH (acquired by Verint).For further information or to contact a member of our senior team, please visit: https://www.fraserfinance.com

## Contacts

5 contacts available for Fraser. Shizune tracks 8 team members at Fraser. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/fraser-finance?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $3.2M–$17M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 38% |
| Biotechnology | 4 | 25% |
| Medical | 2 | 13% |
| Genetics | 2 | 13% |
| Software | 2 | 13% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 31% |
| Funding Round | 3 | 19% |
| Seed | 2 | 13% |
| Series A | 2 | 13% |
| Pre-Seed | 1 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 3 | 19% |
| United Kingdom | 3 | 19% |
| Germany | 2 | 13% |
| Australia | 1 | 6% |
| United States | 1 | 6% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Deborah Herst | Partner | 0 | https://shizune.co/investors/profile/deborah-herst |
| Maxim Seltzer | Senior Advisor | 0 | https://shizune.co/investors/profile/maxim-seltzer |
| Nicholas Field-Johnson | Partner Emeritus | 0 | https://shizune.co/investors/profile/nicholas-field-johnson |
| Olivier Koechlin | Managing Partner | 0 | https://shizune.co/investors/profile/olivier-koechlin |
| Andreas Cser | Venture Partner | 5 | https://shizune.co/investors/profile/andreas-cser |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| The Landbanking Group | The Landbanking Group is a private, social-benefit company that brings together scientists, builders, technology experts and investors. | $11M | Seed | Oct 26, 2023 |  |
| Therapixel | Therapixel develops and commercializes AI-based software for breast cancer detection and characterization | $15.6M | Series B | May 12, 2022 |  |
| PathoQuest | PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $17.4M | Series B | Nov 09, 2021 |  |
| Incision | Incision is a developer of a medical education platform built to offer a standardized method of how to perform a procedure in practical steps and sub-steps. | $6.1M | Series A | May 24, 2021 |  |
| Spearad | Spearad runs a multi format platform for Addressable TV advertising. Our platform helps media owners to monetize content for all available screens. Spearad changes the way advertising is sold, delivered and measured in the new era of personally-targeted and IP based TV. Our technology allows all media players in the television, OTT/VOD andAudio business to fully benefit from the advantages of digital advertising while still maintaining the specifics of audio and television. The company was founded by industry leaders ensuring maximum market acceptance and high standing technological expertise. Spearad is operating worldwide and currently has subsidiaries in Germany, UK and the US. |  | Seed | Dec 10, 2020 |  |
| PathoQuest | PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $8.8M |  | Sep 06, 2019 |  |
| Lumeon | Lumeon is a digital health company that has defined the market for Care Pathway Management (CPM). From scheduling and revenue management to clinical reporting and aftercare, by looking across the end-to end care pathway, Lumeon addresses the system, and not just the symptom, behind healthcare transformation. Lumeon's customers number amongEurope’s fastest growing and most innovative healthcare providers including BUPA, Nuffield Health, Alliance Medical, HCA, Optegra and Newmedica. It is headquartered in London employing over 90 people. | $28M | Series C | Dec 04, 2018 |  |
| Tessian | Tessian’s mission is to secure the human layer. Using machine learning technology, Tessian automatically stops data breaches and security threats caused by human error - like data exfiltration, accidental data loss, business email compromise, and phishing attacks - with minimal disruption to employees' workflow. As a result, employees areempowered to do their best work, without security getting in their way. Founded in 2013, Tessian is backed by renowned investors like Sequoia, Accel, March Capital, and Balderton, and has offices in San Francisco and London. | $13M | Series A | Jun 17, 2018 |  |
| Clinical Genomics Technologies | Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer diagnosis and monitoring. With a broad intellectual property portfolio including more than 20 issued and pending patents, Clinical Genomics has developed and validated a sensitive and specific blood test for colorectal cancer recurrencemonitoring that will be launched in the U.S. in 2016. This 2-gene test, which is based on methylated DNA from two genes, BCAT1 and IKZF1, is currently known by its project name GEMINI. |  | Series B | Jun 01, 2018 |  |
| PathoQuest | PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $4.4M |  | May 15, 2018 |  |

10 of 16 investments shown.

## Co-investors
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 3 deals together
- [SHS Capital](https://shizune.co/investors/profile/shs-gesellschaft-fr-beteiligungsmanagement-mbh) — VC Fund, 3 deals together
- [Verve Ventures](https://shizune.co/investors/profile/verve-ventures) — VC Fund, 3 deals together
- [Amadeus Capital Partners](https://shizune.co/investors/profile/amadeus-capital-partners) — VC Fund, 2 deals together
- [Aurinvest](https://shizune.co/investors/profile/aurinvest) — VC Fund, 2 deals together
- [Charles River Laboratories International](https://shizune.co/investors/profile/charles-river-laboratories-international) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Scott Banister](https://shizune.co/investors/profile/scott-banister) — Angel Investor
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund

## Featured in investor lists
- [Email Investors in United Kingdom](https://shizune.co/investors/email-investors-united-kingdom)
- [Email Investors in Europe](https://shizune.co/investors/email-investors-europe)
- [Email VC Funds in United Kingdom](https://shizune.co/investors/email-vc-funds-united-kingdom)
- [Email VC Funds in Europe](https://shizune.co/investors/email-vc-funds-europe)

## FAQ

### What does Fraser invest in?

Fraser invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Funding Round stage. Most of the 16 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Fraser's check size?

Fraser typically joins rounds of $3.2M–$17M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fraser participates in.

### How do I contact Fraser?

Public channels for Fraser include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Fraser?

The team at Fraser includes Deborah Herst (Partner), Maxim Seltzer (Senior Advisor) and Nicholas Field-Johnson (Partner Emeritus), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co